Praxis Precision Medicines (NASDAQ:PRAX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Praxis Precision Medicines (NASDAQ:PRAX) had its "underperform" rating reaffirmed by analysts at Wedbush.
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.